IDEXX says Q2 2026 revenue rise is driven by double-digit growth in companion animal diagnostics recurring sales
Reuters2026/08/04 13:39- IDEXX posted Q2 2026 revenue growth of about 10% reported, driven by 10.3% organic growth in CAG Diagnostics recurring revenue.
- Performance reflected higher testing volumes despite a 1.3% decline in US same-store clinical visits; net price improvement ran about 4% globally.
- Premium instrument placements totaled 5,265 units, including 1,602 inVue Dx analyzers; instrument revenue fell 20% organically on a tougher comparison.
- Comparable operating margin rose 110 basis points to 35%, aided by recurring revenue mix, productivity, and favorable product costs; EPS was $4.27.
- Full-year guidance increased to revenue of $4.7 billion-$4.75 billion, organic growth of 8.5%-9.7%, and EPS of $14.69-$14.94.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
The 10-year U.S. Treasury yield climbs to 4.8%, erasing the dividend advantage of utility stocks; the sector’s rebound depends on interest rate stabilization rather than technical signals.
As U.S. Treasury yields continue to climb, the American utilities sector is experiencing a significant pullback—a rise in yields not only erodes the relative appeal of the sector’s dividends but also raises financing costs for the most capital-intensive industries within this market.
Euro holds gains above 1.1600 despite robust US jobs data, traders eye ECB rate decision
Port of Tauranga wins fast-track approval for Stella Passage development
Crypto prices
More
